Significance of cytoreductive surgery including bowel resection for patients with advanced ovarian cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 5, 1999, Pages 481-484

  Shimada, Muneaki ^a   Kigawa, Junzo ^a   Minagawa, Yukihisa ^a   Irie, Takashi ^a   Takahashi, Masakuni ^a   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Bowel resection; Cytoreductive surgery; Ovarian cancer; Prognosis

Indexed keywords

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; ILEUS; INTESTINE OBSTRUCTION; INTESTINE RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CANCER; POSTOPERATIVE HEMORRHAGE; PROGNOSIS; RECTOVAGINAL FISTULA; REOPERATION; SEPSIS;

ADULT; AGED; FEMALE; HUMANS; INTESTINES; JAPAN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033510019     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199910000-00012     Document Type: Article

References (22)

1. Muggia FM. Cisplatin update. Semin Oncol 1991;18:1-4.
2. Delgado G, Oram DH, Petrilli ES. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol 1984;18:293-8.
3. Joyeux H, Szawlowski AW, Saint-Abubert B, et al. Aggressive regional surgery for advanced ovarian carcinoma. Cancer 1986; 57:142-7.
4. Campo JM. Felip E, Rubio D, et al. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy. Gynecol Oncol 1994;53:27-32.
5. Ozols RF. Treatment of ovarian cancer: current status. Semin Oncol 1994;21:1-9.
6. Vaccarello L, Rubin SC, Vlamis V, et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 1995;57:61-5.
7. Guidozzi F, Ball JH. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 1994;53:326-30.
8. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-66.
9. Kigawa J, Minagawa Y, Ishihara H, et al. Evaluation of cytoreductive surgery with lymphadenectomy including para-aortic nodes for advanced ovarian cancer. Eur J Surg Oncol 1993;19: 273-8.
10. Griffith CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42:101-4.
11. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-80.
12. Hunter RW, Alexander NDE. Stouter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992;166:504-11.
13. Mukarah A, Hallum AV, Morris M, et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997;64:13-7
14. Kigawa J, Minagawa Y, Ishihara H. et al. Retroperitoneal lymphadenectomy including the para-aortic nodes in patients with stage III ovarian cancer. Am J Clin Oncol 1994;17:230-3.
15. Nguyen HN, Averette HE, Hoskins W, et al. National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer 1993;72:3663-70.
16. Schwartz PE, Chambers JT, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 1994;53:33-7.
17. Wu PC, Lang JH, Huang RL, et al. Intestinal metastasis and operation in ovarian cancer: a report on 62 cases. Baillieres Clin Obstet Gynaecol 1989;3:95-108.
18. Piver MS, Barker T. The potential for optimal (<2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical centre: a prospective study. Gynecol Oncol 1986;24:1-8.
19. Hacker N, Berek JS, Lagasse LD, et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;62: 413-20.
20. Lim JT, Green JA. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol (R Coll Radiol) 1993;5:198-202.
21. McGuire W, Neugut AI, Arikian S, et al. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997;15:640-5.
22. McGuire W, Hoskins WJ, Brady MF, et al. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study. Semin Oncol 1997;24(suppl 2):S2-13-6.